AIV Logo AIV Assistant

Loading...

 Logo Laboratorios Farmaceuticos Rovi, S.A. - ROVI.MC Open Laboratorios Farmaceuticos Rovi, S.A. in new tab

54.95 EUR
P/E
23.59
EPS
2.59
Yield
1.45%
P/B
5.54
ROE
25.01
Beta
0.50
Target Price
79.41 EUR

54.9500 EUR

54.950 EUR

Daily: +0.00%
Key Metrics

Earnings date: Feb. 23, 2026

P/E: 23.59

EPS: 2.59

Book Value: 11.02

Price to Book: 5.54

Debt/Equity: 22.50

% Insiders: 67.333%

Growth

Revenue Growth: -0.10%

Earnings Growth: -0.23%

Estimates

Forward P/E: 22.55

Forward EPS: 2.71

Target Mean Price: 79.41

Dividend

Dividend Yield: 1.45%

Annual dividends: 0.94 EUR

Ex-Div. Date: July 14, 2025

Payout: 42.68%

5y avg Yield: 0.86%

DCF Valuation

Tweak assumptions to recompute fair value for Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

 Logo About Laboratorios Farmaceuticos Rovi, S.A. - (ROVI.MC)

Country: Spain

Sector: Health Care

Website: http://www.rovi.es

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, aseptic filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Exchange Ticker
MEX (Mexico) ROVIN.MX
LSE (United Kingdom) 0ILL.L
PNK (United States) LABFF
MCE (Spain) ROVI.MC
FRA (Germany) 41L.F
STU (Germany) 41L.SG
Dividend Yield

1.45% (5y avg: 0.86%)

Annual Dividends

0.94 EUR

Next ex. div date

July 14, 2025

Payout Ratio

42.68%

Historical Dividends
Year Total Dividends
2026 1.81 EUR
2025 0.94 EUR
2024 1.10 EUR
2023 1.29 EUR
2022 0.96 EUR
2021 0.38 EUR
2020 0.18 EUR
2019 0.08 EUR
2018 0.12 EUR
2017 0.18 EUR
2016 0.14 EUR
2015 0.17 EUR
2014 0.16 EUR
2013 0.14 EUR
2012 0.13 EUR
2011 0.17 EUR
2010 0.14 EUR
2009 0.09 EUR
2008 0.08 EUR

Yearly aggregated dividends

Dividends

Laboratorios Farmaceuticos Rovi, S.A.
Jul 16, 2025 Paid
Dividend
0.9351 EUR

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion